[1]
|
E. Grotewold, “The science of flavonoids”, Springer, New York, 2006.
|
[2]
|
Y.M. Lin, Y. Zhou, M. Flavin, L.M. Zhou, W. Nie and F.C. Chen, “Chalcones and flavonoids as anti-tuberculosis agents”, Bioorganic & Medicinal Chemistry, Vol. 10, 2002, pp. 2795-2802.
|
[3]
|
M.L. Go, X. Wu and X.L. Liu, “Chalcones: an update on cytotoxic and chemoprotective properties”, Current Medicinal Chemistry, Vol. 12, 2005, pp. 483-499.
|
[4]
|
Z. Nowakowska, “A review of anti-infective and anti-inflammatory chalcones”, European Journal of Medicinal Chemistry, Vol. 42, 2007, pp. 125-137.
|
[5]
|
S. Velavan, K. Nagulendran, R. Mahesh and V. Begum, “In vitro antioxidant activity of Asparagus racemosusroot”, Pharmacognosy Magazine, 1998, ISSN: 0973- 1296.
|
[6]
|
M. Okawa, J. Kinjo, T. Nohara and M. Ono, “DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity of flavonoids obtained from some medicinal plants”, Biological and Pharmaceutical Bulletin, Vol. 24, 2001, pp. 1202-1205.
|
[7]
|
E. Cadenas and L. Packer, “Handbook of antioxidants”, Marcel Dekker, New York, 1996.
|
[8]
|
C. Rice-Evans and L. Packer, “Flavonoids in health and disease”, Marcel Dekker, New York, 2003.
|
[9]
|
Prakash, R. Kumar and V. Parkash, “Synthesis and antifungal activity of some new 3-hydroxy-2-(1-phenyl-3- aryl-4-pyrazolyl)chromones”, European Journal of Medicinal Chemistry, Vol. 43, 2008, pp. 435-440.
|
[10]
|
Prakash, R. Kumar and R. Sehrawat, “Synthesis and antibacterial activity of some new 2,3-dimethoxy-3-hydroxy- 2-(1-phenyl-3-aryl-4-pyrazolyl)chromanones”, European Journal of Medicinal Chemistry, Vol. 44, 2009, pp. 1763- 1767.
|
[11]
|
B. Bandgar, S. Gawande, R. Bodade, N. Gawande and C. Khobragade, “Synthesis and biological evaluation of a novel series of pyrazolechalcones as anti-inflammatory, antioxidant and antimicrobial agents”, Bioorganic & Medicinal Chemistry, Vol. 17, 2009, pp. 8168-8173.
|
[12]
|
H. Adibi, J.S. Mojarrad, H. Asgharloo and G. Zarrini, “Synthesis, in vitro antimicrobial and antioxidant activities of chalcone and flavone derivatives holding allylic substitutions”, Medicinal Chemistry Research, 2010, pp. 1-7.
|
[13]
|
N.S. Joshi, A.A. Shaikh, A.P. Deshpande, B.K. Karale, S.B. Bhirud and C.H. Gill, “Synthesis, characterization and antimicrobial activities of some fluorine containing 2 (1-phenyl-3-aryl-1H-pyrazol-4-yl)-3-chlorochromones, 2- (1-Phenyl-3-aryl-1H-pyrazol-4-yl)chromones and 5-(1- phenyl-3-aryl-1H-pyrazol-4-yl)-3-(2-hydroxyphenyl)-4,5-dihydropyrazolines”, Indian Journal of Chemistry, Vol. 44B, 2005, pp. 422-425.
|
[14]
|
TT. Dao, Y.S. Chi, J. Kim, H.P. Kim, S. Kim and H. Park, “Synthesis and PGE2 inhibitor activity of 5,7-dihydroxy- flavones and their O-methylate flavone analogs”, Archives of Pharmacal Research, Vol. 26, 2003, pp. 345-350.
|
[15]
|
M. Hiersemann and U. Nubbemeyer, “The Claisen rearrangement: methods and applications”, Wiley-VCHVerlag GmbH, Weinheim, 2007.
|
[16]
|
NCCLS - National Committee for Clinical Laboratory Standards (1985) Approved standard document M-7A, Villanova, P.A., 1985.
|
[17]
|
P.R. Murray, E. Baron, J. Jorgensen, M. Landry and M. Pfaller, “Manual of clinical microbiology” (9th ed), American Society of Microbiology, Washington D.C., 2007.
|
[18]
|
K. Kato, S. Terao, N. Shimamoto and M. Hirata, “Studies on scavengers of active oxygen species. 1. Synthesis and biological activity of 2-O-alkylascorbic acids”, Journal of Medicinal Chemistry, Vol. 31, 1988, pp. 793-798.
|
[19]
|
Padmaja, T. Payani, G.D. Reddy and V. Padmavathi, “Synthesis, antimicrobial and antioxidant activities of substituted pyrazoles, isoxazoles, pyrimidine and thioxopyrimidine derivatives”, European Journal of Medicinal Chemistry, Vol. 44, 2009, pp. 4557-4566
|